CD274 and neoplasm: Pembrolizumab works by blocking the PD-1 and keeping its ligands PD-L1 and PD-L2 from binding to it to reduce inhibitory signaling and restore the patient’s natural tumor specific T-cell-mediated immune responses and provide a favorable circumstance for CIK cell infusion.